![Table 5 from Continuous nebulization therapy for asthma with aerosols of beta2 agonists. | Semantic Scholar Table 5 from Continuous nebulization therapy for asthma with aerosols of beta2 agonists. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/01a92c5ac112f986887d4d53e88aa803f480ad8c/8-Table5-1.png)
Table 5 from Continuous nebulization therapy for asthma with aerosols of beta2 agonists. | Semantic Scholar
![High-Dose Albuterol by Metered-Dose Inhaler Plus a Spacer Device Versus Nebulization in Preschool Children With Recurrent Wheezing: A Double-Blind, Randomized Equivalence Trial | Semantic Scholar High-Dose Albuterol by Metered-Dose Inhaler Plus a Spacer Device Versus Nebulization in Preschool Children With Recurrent Wheezing: A Double-Blind, Randomized Equivalence Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/afefa36335490de6d17491398f4e090de007290a/4-Table2-1.png)
High-Dose Albuterol by Metered-Dose Inhaler Plus a Spacer Device Versus Nebulization in Preschool Children With Recurrent Wheezing: A Double-Blind, Randomized Equivalence Trial | Semantic Scholar
![PDF] Albuterol aerosol delivered via metered-dose inhaler to intubated pediatric models of 3 ages, with 4 spacer designs. | Semantic Scholar PDF] Albuterol aerosol delivered via metered-dose inhaler to intubated pediatric models of 3 ages, with 4 spacer designs. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a4ba725b7e3c0b3f14d07b7d5acf5a487a0af235/2-Table1-1.png)
PDF] Albuterol aerosol delivered via metered-dose inhaler to intubated pediatric models of 3 ages, with 4 spacer designs. | Semantic Scholar
![Albuterol Sulfate Inhalation Solution0.042% (1.25 mg*/3 mL) and 0.021% (0.63 mg*/3 mL)(*Potency expressed as albuterol, equivalent to 1.5 mgand 0.75 mg albuterol sulfate) Revised: January 2017 Rx only Albuterol Sulfate Inhalation Solution0.042% (1.25 mg*/3 mL) and 0.021% (0.63 mg*/3 mL)(*Potency expressed as albuterol, equivalent to 1.5 mgand 0.75 mg albuterol sulfate) Revised: January 2017 Rx only](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-7.jpg&id=427002)
Albuterol Sulfate Inhalation Solution0.042% (1.25 mg*/3 mL) and 0.021% (0.63 mg*/3 mL)(*Potency expressed as albuterol, equivalent to 1.5 mgand 0.75 mg albuterol sulfate) Revised: January 2017 Rx only
![Pharmaceutics | Free Full-Text | Quantifying Delivered Dose with Jet and Mesh Nebulizers during Spontaneous Breathing, Noninvasive Ventilation, and Mechanical Ventilation in a Simulated Pediatric Lung Model with Exhaled Humidity Pharmaceutics | Free Full-Text | Quantifying Delivered Dose with Jet and Mesh Nebulizers during Spontaneous Breathing, Noninvasive Ventilation, and Mechanical Ventilation in a Simulated Pediatric Lung Model with Exhaled Humidity](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-13-01179/article_deploy/html/images/pharmaceutics-13-01179-g001-550.jpg?1628038134)
Pharmaceutics | Free Full-Text | Quantifying Delivered Dose with Jet and Mesh Nebulizers during Spontaneous Breathing, Noninvasive Ventilation, and Mechanical Ventilation in a Simulated Pediatric Lung Model with Exhaled Humidity
![Replacing nebulizers by MDI-spacers for bronchodilator and inhaled corticosteroid administration: Impact on the utilization of hospital resources | Semantic Scholar Replacing nebulizers by MDI-spacers for bronchodilator and inhaled corticosteroid administration: Impact on the utilization of hospital resources | Semantic Scholar](https://ai2-s2-public.s3.amazonaws.com/figures/2017-08-08/3101bfd9623e6639c72fe39afc806a9d4c9b4164/4-Table1-1.png)
Replacing nebulizers by MDI-spacers for bronchodilator and inhaled corticosteroid administration: Impact on the utilization of hospital resources | Semantic Scholar
![Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis | Asthma Research and Practice | Full Text Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis | Asthma Research and Practice | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs40733-020-00059-5/MediaObjects/40733_2020_59_Fig1_HTML.png)